Denali Therapeutics Inc.

NASDAQ:DNLI

Biotechnology

Healthcare
$18.40 +0.40%

+$0.09 today

Market cap
$2.95B
Beta
1.01
P/E (TTM)
-8.7
EPS (TTM)
-$2.72
52W Low $12.58High $24.65

Volume 2.37M

Average 1.84M

DNLI Common Stock Issued

Cash raised by issuing new shares.

Denali Therapeutics Inc.NASDAQ: DNLI

Common Stock Issued · Q2 FY2026 · quarter ended Jun 2026

Common stock issued grows, but more slowly than its trailing trend

Q2 FY2026 common stock issued of $15.01M rose 269.9% year over year, behind the +1490.1% change in trailing-twelve-month common stock issued. Sequentially, it fell 21.3% from the prior quarter. Over 3 fiscal years it compounded at -12.7% a year.

Context

  • Common stock issued increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +269.9% toward the trailing-twelve-month pace of +1490.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$15.01M-21.3% QoQ
Last fiscal yearDec 2025
$197.38M-60.5% YoY
LTMJun 2026
$226.8M+1490.1% YoY
Common Stock Issued past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+269.9%——
1 year-60.5%——
3-year CAGR-12.7%——
5-year CAGR——
10-year CAGR——

Common Stock Issued history

USD · from the cash flow

Latest · FY2025
197.38M USD
Year-over-year change
-60.5%
4-year CAGR
+78.7%

Common Stock Issued vs competitors

How DNLI compares with its peers on the latest reported figures

  • DNLI's LTM Jun 2026 common stock issued of $226.8M is the 5th largest of the 11 companies compared; the peer median is $191.1M.
  • Its year-over-year change of +1490.1% is the 2nd highest of 10, against a peer median of +147.9%.
  • Common stock issued amounts to 6293.0% of revenue for DNLI, versus a peer median of 65.4%.
DNLI Competitors Peer median
Common Stock Issued for DNLI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$1.24B +509.2%+319.2%—
BHVNBiohaven Ltd.LTM Jun 2026$371.8M +6.5%-12.6%—
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$277.53M +7110.3%-15.6%—
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$271.53M +72.2%+104.2%1357.6%
DNLIDenali Therapeutics Inc.LTM Jun 2026$226.8M +1490.1%-12.7%6293.0%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$211.21M +147.9%+211.5%22.0%
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$171M +67.5%+42.5%4.6%
PMNProMIS Neurosciences, Inc.LTM Jun 2026$90.96M +228.9%+46.3%—
CGTXCognition Therapeutics, Inc.LTM Mar 2026$35.67M +162.3%+91.0%—
ALECAlector, Inc.LTM Mar 2026$20.02M —+64.2%108.7%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$11.15M -31.8%——
Peer median (excluding DNLI) $191.1M+147.9%+64.2%65.4%

Competitors are the stored peer set for DNLI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(290.58M)(325.99M)(145.22M)(422.77M)(512.54M)
Depreciation & Amortization8.59M10.38M16.73M8.99M14.81M
Deferred Income Tax00000
Stock-Based Compensation85.25M99.85M108.1M102.88M99.63M
Change in Working Capital(20.41M)(24.03M)(289.93M)16.94M149K
Accounts Receivables00000
Inventory00000
Accounts Payables3.71M2.27M2.43M1.44M(7.52M)
Other Working Capital(24.12M)(26.3M)(292.36M)15.5M7.67M
Other Non-Cash Items5.76M(4.93M)(47.67M)(53.73M)(14.65M)
Operating Cash Flow(211.39M)(244.72M)(357.99M)(347.69M)(412.6M)
Capital Expenditures(8.5M)(17.83M)(12.94M)(15.91M)(9.5M)
Acquisitions (Net)0123.55M000
Purchases of Investments(1.42B)(1.12B)(1.81B)(1.23B)(441.26M)
Sales of Investments1.41B991.49M2.08B1.16B706.05M
Other Investing Activities0(123.55M)000
Investing Cash Flow(21.63M)(141.39M)249.31M(88.76M)255.28M
Debt Repayment000(32.34M)(8.17M)
Common Stock Issued19.35M296.22M17.82M499.25M197.38M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities014.46M017.39M0
Financing Cash Flow19.35M310.67M17.82M484.3M189.22M
Effect of Forex Changes00(75K)00
Net Change in Cash(213.67M)(75.43M)(90.94M)47.85M31.9M
Free Cash Flow(219.89M)(262.55M)(370.93M)(363.61M)(422.1M)

Denali Therapeutics Inc.

NASDAQ:DNLI

Intrinsic Alpha fair value

Locked

Current Price

$18.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.